Traws Pharma, Inc. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
Traws Pharma, Inc. (TRAW) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of $39.77 million for the 12-month period ending 2014-12-31, per its 10-K filed 2016-03-28.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2016-03-28
- Traws Pharma, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2014-12-31 was $14.99M.
- Traws Pharma, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2014-09-30 was $0.00.
- Traws Pharma, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2014-06-30 was $14.85M.
- Traws Pharma, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2014-03-31 was $9.93M.
- Traws Pharma, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was $39.77M.
- Traws Pharma, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2013 was -$40.60M.
- Traws Pharma, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2012 was -$279.00K.
- Traws Pharma, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2011 was -$241.00K.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2014-12-31 | $14.99M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-28 | $14.99M derived: sum of 2 quarters · filed 2016-03-28 | $29.84M derived: sum of 3 quarters · filed 2016-03-28 | $39.77M 10-K · filed 2016-03-28 |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | $14.85M derived: sum of 2 quarters · filed 2015-11-12 | $24.78M 10-Q · filed 2015-11-12 | $24.68M derived: sum of 4 quarters · filed 2015-11-12 |
| 2014-06-30 | $14.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | $24.78M 10-Q · filed 2015-08-13 | $24.68M derived: sum of 3 quarters · filed 2015-08-13 | -$15.35M derived: sum of 4 quarters · filed 2015-08-13 |
| 2014-03-31 | $9.93M 10-Q · filed 2015-05-15 | $9.83M derived: sum of 2 quarters · filed 2015-05-15 | -$30.20M derived: sum of 3 quarters · filed 2015-05-15 | -$30.39M derived: sum of 4 quarters · filed 2015-05-15 |
| 2013-12-31 | -$94.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-30 | -$40.13M derived: sum of 2 quarters · filed 2015-03-30 | -$40.31M derived: sum of 3 quarters · filed 2015-03-30 | -$40.60M 10-K · filed 2015-03-30 |
| 2013-09-30 | -$40.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-14 | -$40.22M derived: sum of 2 quarters · filed 2014-11-14 | -$40.51M 10-Q · filed 2014-11-14 | -$40.65M derived: sum of 4 quarters · filed 2015-03-30 |
| 2013-06-30 | -$189.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-14 | -$473.00K 10-Q · filed 2014-08-14 | -$621.00K derived: sum of 3 quarters · filed 2015-03-30 | -$746.00K derived: sum of 4 quarters · filed 2015-03-30 |
| 2013-03-31 | -$284.00K 10-Q · filed 2014-05-15 | -$432.00K derived: sum of 2 quarters · filed 2015-03-30 | -$557.00K derived: sum of 3 quarters · filed 2015-03-30 | |
| 2012-12-31 | -$148.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-30 | -$273.00K derived: sum of 2 quarters · filed 2015-03-30 | -$279.00K 10-K · filed 2015-03-30 | |
| 2012-09-30 | -$125.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-14 | -$131.00K 10-Q · filed 2013-11-14 | ||
| 2012-06-30 | -$6.00K 10-Q · filed 2013-09-06 | |||
| 2011-12-31 | -$241.00K 10-K · filed 2014-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |